- Home
- JKHY vs BBIO Comparison
JKHY vs BBIO Comparison
Compare JKHY & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JKHY | BBIO |
|---|---|---|
| Founded | 1976 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 15.3B |
| IPO Year | 2000 | 2019 |
Fundamental Metrics
Financial Performance| Metric | JKHY | BBIO |
|---|---|---|
| Price | $158.99 | $69.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 22 |
| Target Price | ★ $196.42 | $79.91 |
| AVG Volume (30 Days) | 1.1M | ★ 2.8M |
| Earning Date | 04-27-2026 | 04-09-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | 19.31 | ★ 27.09 |
| EPS | ★ 3.70 | N/A |
| Revenue | ★ $1,536,603,000.00 | $221,902,000.00 |
| Revenue This Year | $8.16 | $128.68 |
| Revenue Next Year | $6.19 | $83.58 |
| P/E Ratio | $43.51 | ★ N/A |
| Revenue Growth | 7.37 | ★ 2285.27 |
| 52 Week Low | $144.13 | $28.33 |
| 52 Week High | $196.00 | $84.94 |
Technical Indicators
Market Signals| Indicator | JKHY | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 32.98 | 39.59 |
| Support Level | $157.31 | $72.82 |
| Resistance Level | $161.69 | $76.81 |
| Average True Range (ATR) | 5.97 | 4.39 |
| MACD | -1.27 | -0.47 |
| Stochastic Oscillator | 16.80 | 26.97 |
Price Performance
Historical ComparisonAbout JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing for US banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.